|Study Type:||Phase I|
|Stage:||Primary analysis complete|
|Study Start Date:||NA|
|Study Made Public:||NA|
A worldwide, Phase I, dose-escalating study of the safety, tolerability, and immunogenicity of a 3-dose regimen of the MRKAd5 HIV-1 gag vaccine in healthy adults
HVTN 050 (Merck V520-018) is a Phase I clinical trial to evaluate the safety and immunogenicity of MRKAd5 HIV-1 gag (Ad5).
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.